Table 1 Clinicopathological characteristics of patients with PC in cohorts 1, 2, and 3
Characteristic | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
Malignant samples, N | 83 | 16 | 132 |
Age (years) at RP, median (range) | 65 (45–76) | N/A | 64 (50–76) |
Preoperative PSA (ng/ml) | |||
≤ 10, N (%) | 39 (47.0%) | N/A | 42 (31.8%) |
> 10, N (%) | 39 (47.0%) | N/A | 90 (68.2%) |
Unknown, N (%) | 5 (6.0%) | N/A | 0 (0.0%) |
ISUP Grade Group | |||
≤ 3, N (%) | 63 (75.9%) | 9 (56.2%) | 110 (83.3%) |
> 3, N (%) | 20 (24.1%) | 7 (43.7%) | 22 (16.7%) |
Pathological T-stage | |||
T2, N (%) | 51 (61.4%) | 4 (25.0%) | 85 (64.4%) |
T3, N (%) | 31 (37.4) | 10 (62.5%) | 47 (35.6%) |
Unknown/T4, N (%) | 1 (1.2%) | 2 (12.5%) | 0 (0.0%) |
Biochemical recurrence (BCR) status | |||
BCR, N (%) | 28 (33.7%) | 6 (37.5%) | 70 (53.0%) |
BCR-free, N (%) | 31 (63.9%) | 10 (62.5%) | 62 (47.0%) |
Unknown, N (%) | 2 (2.4%) | 0 (0.0%) | 0 (0.0%) |
Total follow-up in months, median (range) | 52.4 (17.6-178.9) | N/A | 147.7 (6.0-267.6) |